Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Detection of IgG antibodies directed against heparin/platelet factor 4 complexes that are implicated in the pathogenesis of immune-mediated type II heparin-induced thrombocytopenia (HIT-II).
Clinical picture of HIT type II:
-In patients not previously exposed to heparin
-Decrease in platelet count (thrombocytopenia) of 50% or more from baseline or postoperative peak
-Onset of thrombocytopenia beginning approximately 5 to 10 days after initiation of heparin this may or may not be associated with new or progressive thrombosis in patients treated with heparin
Patients previously exposed to heparin (especially within the preceding 100 days), in addition to the above findings, the onset of thrombocytopenia could occur within 24 to 48 hours after reexposure to heparin
Enzyme-Linked Immunosorbent Assay (ELISA)